Acción LX31 LEXICON PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Lexicon Pharmaceuticals, Inc. BOERSE MUENCHEN

Acciones

LX31

US5288723027

Mercado cerrado - BOERSE MUENCHEN
Otros sitios de cotización
 13:43:00 30/12/2021 		Varia. Cinco días. Varia. 1 de enero.
3,71 EUR +3,23 % Gráfico intradía de Lexicon Pharmaceuticals, Inc. -.--% -14,52 %
08/07 Lexicon Pharmaceuticals nombra a Mike Exton consejero delegado y a Jeff Wade jefe de operaciones MT
08/07 Lexicon Pharmaceuticals, Inc. anuncia cambios en el cargo de consejero delegado CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer
Lexicon Pharmaceuticals, Inc. Announces Management Changes
Lexicon Enters into A Sixth Amendment to Its Loan and Security Agreement with Oxford Finance LLC
Sector Update: Health Care Stocks Gain in Late Afternoon
Lexicon Pharmaceuticals Resubmits New Drug Application for Potential Type 1 Diabetes Therapy
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Lexicon: Q1 Earnings Snapshot
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción LXRX
  4. Acción LX31
  5. Noticias Lexicon Pharmaceuticals, Inc.
  6. Otros idiomas